TBPH: Theravance Biopharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 462.29
Enterprise Value ($M) 359.86
Book Value ($M) 213.00
Book Value / Share 4.39
Price / Book 2.17
NCAV ($M) -35.46
NCAV / Share -0.73
Price / NCAV -13.04

Profitability (mra)
Return on Invested Capital (ROIC) -0.21
Return on Assets (ROA) -0.10
Return on Equity (ROE) -0.15

Liquidity (mrq)
Quick Ratio 5.39
Current Ratio 5.39

Balance Sheet (mrq) ($M)
Current Assets 133.54
Assets 382.00
Liabilities 169.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 57.42
Operating Income -53.29
Net Income -55.19
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -27.00
Cash from Investing -32.70
Cash from Financing -198.93

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
03-05 13D/A Weiss Asset Management LP
02-14 13G Irenic Capital Management LP 5.50
02-13 13G/A Vanguard Group Inc 7.01 -37.23
02-08 13G/A BlackRock Inc. 9.20 -13.98
07-10 13G/A Baupost Group Llc/ma 12.84 -35.03

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2023-05-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 27,428 271,778 10.09
2024-04-17 26,126 307,877 8.49
2024-04-16 50,409 472,501 10.67
2024-04-15 37,891 517,519 7.32

(click for more detail)

Similar Companies
STRO – Sutro Biopharma, Inc. SUPN – Supernus Pharmaceuticals, Inc.
TARA – Protara Therapeutics, Inc. TCRX – TScan Therapeutics, Inc.
TENK – TenX Keane Acquisition


Financial data and stock pages provided by
Fintel.io